Context Therapeutics Stock Price To Sales
| CNTX Stock | USD 1.36 0.03 2.16% |
Context Therapeutics fundamentals help investors to digest information that contributes to Context Therapeutics' financial success or failures. It also enables traders to predict the movement of Context Stock. The fundamental analysis module provides a way to measure Context Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Context Therapeutics stock.
| Last Reported | Projected for Next Year |
Context | Price To Sales |
Context Therapeutics Company Price To Sales Analysis
Context Therapeutics' Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Context Price To Sales Driver Correlations
Understanding the fundamental principles of building solid financial models for Context Therapeutics is extremely important. It helps to project a fair market value of Context Stock properly, considering its historical fundamentals such as Price To Sales. Since Context Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Context Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Context Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
| Competition |
Based on the latest financial disclosure, Context Therapeutics has a Price To Sales of 0.0 times. This is 100.0% lower than that of the Pharmaceuticals sector and 100.0% lower than that of the Health Care industry. The price to sales for all United States stocks is 100.0% higher than that of the company.
Context Price To Sales Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Context Therapeutics' direct or indirect competition against its Price To Sales to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Context Therapeutics could also be used in its relative valuation, which is a method of valuing Context Therapeutics by comparing valuation metrics of similar companies.Context Therapeutics is currently under evaluation in price to sales category among its peers.
Context Fundamentals
| Return On Equity | -0.3 | ||||
| Return On Asset | -0.19 | ||||
| Current Valuation | 19.69 M | ||||
| Shares Outstanding | 75 M | ||||
| Shares Owned By Insiders | 1.44 % | ||||
| Shares Owned By Institutions | 76.40 % | ||||
| Number Of Shares Shorted | 802.81 K | ||||
| Price To Book | 1.24 X | ||||
| EBITDA | (25.06 M) | ||||
| Net Income | (23.96 M) | ||||
| Cash And Equivalents | 42.92 M | ||||
| Cash Per Share | 2.69 X | ||||
| Total Debt | 4.19 M | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 14.64 X | ||||
| Book Value Per Share | 0.74 X | ||||
| Cash Flow From Operations | (21.05 M) | ||||
| Short Ratio | 2.79 X | ||||
| Earnings Per Share | (0.88) X | ||||
| Target Price | 7.7 | ||||
| Beta | 2.25 | ||||
| Market Capitalization | 104.25 M | ||||
| Total Asset | 16.06 M | ||||
| Retained Earnings | (68.05 M) | ||||
| Working Capital | 11.86 M | ||||
| Net Asset | 16.06 M |
About Context Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Context Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Context Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Context Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Context Stock Analysis
When running Context Therapeutics' price analysis, check to measure Context Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Context Therapeutics is operating at the current time. Most of Context Therapeutics' value examination focuses on studying past and present price action to predict the probability of Context Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Context Therapeutics' price. Additionally, you may evaluate how the addition of Context Therapeutics to your portfolios can decrease your overall portfolio volatility.